
Hunter residents at high risk of developing Alzheimer's Disease will be given access to a clinical trial involving a breakthrough drug that appears to slow the development of the disease.
The Hunter Medical Research Institute is the only site in regional Australia selected to screen people into a new clinical trial of Lecanemab.